Navigation Links
Clinical Update - Debio 025 in Hepatitis C
Date:1/26/2009

LAUSANNE, Switzerland, January 26 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today the randomisation of its first patient in a phase IIb clinical study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C (HCV) effect. This multinational, double blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of three different treatment regimens combining Debio 025 with Peg interferon alpha 2a (peg-IFNalpha2a) and ribavirin in treatment-naive chronic HCV genotype 1 patients.

During this 72 week trial, on top of the Standard of Care (SOC) treatment consisting of peg-IFNalpha2a 180 microgram once weekly and ribavirin 1000 or 1200 mg/day, patients will receive an oral dose of 600 mg of Debio 025. Three different triple combination regimens will be compared to the SOC treatment. The Company aims to evaluate whether there is an increase in the proportion of patients who achieve a sustained viral response (HCV RNA < 10 U/mL 24 weeks after treatment end) with Debio 025, compared to the SOC treatment. The trial will include 272 treatment-naive chronic HCV genotype 1 patients. Results of the study are expected in Q1 2011.

"We believe that the future of chronic HCV treatment lies in the combination of drugs with different mechanisms of action and potential additive or synergistic antiviral effects. For this reason we are investigating the use of Debio 025 combined with the current peg-IFNalpha2a/ribavirin dual therapy. We are optimistic that this combination will reduce the risk of treatment failure for HCV patients and maximise their chances of sustained viral response," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group.

"With over 170 million people infected with HCV worldwide, there i
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... , Spanje, July 4, 2015 /PRNewswire/ ... Y-90 harsmicrosferen aan eerstelijns chemotherapie voor patiënten ... lever (mCRC) verlengt de progressievrije overleving in ... niet-resectabele, gemetastaseerde colorectale kanker (mCRC) die alleen ... verbetering gezien in progressievrije overleving (PFS) in ...
(Date:7/3/2015)... 2015 According to a ... Rhythm Management Market ECG, Implantable Loop Recorder, Manual ... Defibrillator, Dual Chamber Pacemaker, CRT-D, CRT-P - Global ... Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) ... by 2020 from $21,137.7 Million in 2015, at ...
(Date:7/3/2015)... July 3, 2015  Obsidian HDS, the developer of ... service for the management of data on pharmaceutical and ... PharmaShine now includes the 2014 Open Payments General and ... on June 30. The data disclosed on Open Payments ... industry and providers totaling $6.49 billion and is the ...
Breaking Medicine Technology:Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2
... CVS Caremark Corporation (NYSE: CVS ) ... 3, 2011, at 8:30 a.m. (ET) with analysts and ... as well as its initial guidance for 2011. ... the conference call will be broadcast simultaneously through the ...
... the stethoscope for the 21st century. Ultrasound is ... patients quickly and accurately. It,s been around for decades, but ... years, making the machines smaller, cheaper and smarter. ... making its own mark with ultrasound. It,s the only medical ...
Cached Medicine Technology:U of South Carolina, a Leader in Ultrasound Education, Hosts World Congress in Spring 2U of South Carolina, a Leader in Ultrasound Education, Hosts World Congress in Spring 3
(Date:7/2/2015)... ... ... Many Fourth of July celebrations will include fireworks this summer, so it’s ... some tips to promote the proper use of fireworks. , According to the U.S. ... with fireworks-related injuries in the month surrounding the Fourth of July. Amica is sharing ...
(Date:7/2/2015)... ... July 02, 2015 , ... In 2012, Patrick Achebe realized that the gift of poetry ... sat down to write his first poem, and three years later he was publishing an ... and worth sharing with the world. "I have always believed that the best way to ...
(Date:7/2/2015)... , ... July 02, 2015 , ... As Americans celebrate ... the hot temps, skin cancer is on the rise. July is UV Safety Month, ... raising awareness about the importance of getting skin checks. Experts say most skin cancers ...
(Date:7/2/2015)... CITY, GA (PRWEB) , ... July 02, 2015 , ... ... their newest innovation in compression socks designed for men. , For style that’s ... socks into their daily routine. This is great news for men everywhere because a ...
(Date:7/2/2015)... ... 02, 2015 , ... The ZAC Foundation, a national leader in water safety ... on how to stay water safe with the help of a young polar bear ... ZAC Foundation co-founders, follows Zeke’s water safety journey. Zeke, who is afraid of ...
Breaking Medicine News(10 mins):Health News:6 Fireworks Safety Tips from Amica Insurance 2Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:Local Physicians Warn of Holiday Health Hazards 2Health News:Local Physicians Warn of Holiday Health Hazards 3Health News:Local Physicians Warn of Holiday Health Hazards 4Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3
... transient neurological attacks, such as temporary amnesia or ... and dementia, according to a study in the ... neurological attacks (TNAs) are episodes involving temporary (less ... be nonfocal (that can include nonlocalizing cerebral symptoms), ...
... Early practice for youngsters can reduce risk of shoulder ... News) -- Playing catch with your young pitcher months before ... pitfall: torn rotator cuff injuries, according to doctors at Methodist ... - a high pitch count and throwing curve balls -- ...
... are among those that pose a threat, experts warn ... lead in toys has attracted a great deal of attention ... may pose to children. For example, some toys can damage ... There were more than 210,000 toy-related injuries treated in U.S. ...
... today announced that it has received a letter from ... bid price of the Company,s common,stock has closed below ... Marketplace Rule 4310(c)(4) (the "Rule").,Therefore, in accordance with Marketplace ... calendar days, or until June 16, 2008 to regain,compliance. ...
... 24 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ... and products in the People,s Republic of China, ... the listing of its common stock on,the NASDAQ ... NASDAQ Capital,Market to the NASDAQ Global Market has ...
... PALM BEACH, Fla., Dec. 24 Veterans Affairs Medical,Center ... that could help reduce,the spiraling cost of healthcare nationwide., ... the area to adopt a privacy,curtain for hospital beds ... less maintenance than conventional hospital bed curtains. The,innovation called ...
Cached Medicine News:Health News:Some types of temporary neurological problems associated with increased risk for stroke, dementia 2Health News:Some types of temporary neurological problems associated with increased risk for stroke, dementia 3Health News:Playing Catch in Winter Could Save Kids' Pitching Arms 2Health News:Beware Holiday Toys That Can Injure Young Eyes 2Health News:QMed, Inc. Receives NASDAQ Letter 2Health News:Chindex International, Inc. Announces Transfer to NASDAQ Global Market 2Health News:Chindex International, Inc. Announces Transfer to NASDAQ Global Market 3Health News:VA Hospital Draws Curtain on Innovation That Could Help Reduce Spiraling Cost of Hospital Maintenance Nationwide 2
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
... ToRCH Plus Control is a ... monitor the performance of the ... and assays. A weak positive ... you to monitor the performance ...
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: